📰 Abt News
Page 168 - Abt News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Abt. Real-time updates on events, politics, business and more.
April 25, 2023
Cottonwood Capital Advisors LLC trimmed its holdings in Abbott Laboratories (NYSE:ABT – Get Rating) by 11.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,166 shares of the healthcare product maker’s stock after selling 270 shares during the period. Cottonwood Capital Advisors LLC’s […]
April 25, 2023
Legacy Financial Advisors Inc. increased its stake in shares of Abbott Laboratories (NYSE:ABT – Get Rating) by 16.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,794 shares of the healthcare product maker’s stock after acquiring an additional 799 shares during the […]
April 25, 2023
Absher Wealth Management LLC lifted its position in Abbott Laboratories (NYSE:ABT – Get Rating) by 3.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 172,908 shares of the healthcare product maker’s stock after purchasing an additional 6,032 shares during […]
April 25, 2023
Synovus Financial Corp boosted its holdings in shares of Abbott Laboratories (NYSE:ABT – Get Rating) by 3.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 242,356 shares of the healthcare product maker’s stock after purchasing an additional 8,153 shares during […]
April 25, 2023
HM Payson & Co. decreased its position in Abbott Laboratories (NYSE:ABT – Get Rating) by 1.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 439,774 shares of the healthcare product maker’s stock after selling 6,502 shares during the period. Abbott Laboratories makes up 1.2% of HM Payson & Co.’s investment portfolio, making the […]
April 24, 2023
Abbott Laboratories (NYSE:ABT – Get Rating) had its target price upped by Raymond James from $116.00 to $123.00 in a report released on Thursday, The Fly reports. Other equities research analysts also recently issued reports about the stock. Citigroup raised their target price on shares of Abbott Laboratories from $125.00 to $130.00 and gave the […]
April 24, 2023
Abbott Laboratories (NYSE:ABT – Get Rating) had its target price upped by Barclays from $125.00 to $127.00 in a research report sent to investors on Thursday morning, The Fly reports. They currently have an overweight rating on the healthcare product maker’s stock. A number of other research firms have also recently weighed in on ABT. […]
April 24, 2023
Arcblock (ABT) traded 2.1% lower against the U.S. dollar during the one day period ending at 20:00 PM Eastern on April 23rd. One Arcblock token can now be bought for about $0.11 or 0.00000402 BTC on popular exchanges. Arcblock has a total market cap of $10.92 million and approximately $202,064.15 worth of Arcblock was traded […]
April 24, 2023
Asset Management One Co. Ltd. lessened its holdings in shares of Abbott Laboratories (NYSE:ABT – Get Rating) by 4.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 792,689 shares of the healthcare product maker’s stock after selling 32,687 shares during the quarter. Asset Management […]
April 24, 2023
Warther Private Wealth LLC decreased its holdings in shares of Abbott Laboratories (NYSE:ABT – Get Rating) by 33.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,432 shares of the healthcare product maker’s stock after selling 2,241 shares during the period. Warther Private […]